Do topical ocular antihypertensives affect Dacryocystorhinostomy outcomes: The Coventry experience

Mandal, Priyanka; Ahluwalia, Harpreet

doi:10.1038/s41433-021-01468-3

Cited by 4 publications

(10 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to previous studies, 5-23% [2][3][4] of patients were receiving anti-glaucoma treatment when lacrimal drainage system obstruction was being diagnosed. In our study of 795 patients with NLDO, 30 (3.8%) used topical anti-glaucoma medications during EDCR surgery.…”

Section: Discussionmentioning

confidence: 99%

“…Likewise, they may induce inflammation and fibrosis in the epithelium and subepithelial tissue of the lacrimal drainage system, causing NLDO [4,13,14]. Furthermore, previous studies have reported that topical antiglaucoma medications may exaggerate the scarring response in the mucosa of the lacrimal drainage system and affect the success rate of EDCR [3,9]. Di Maria et al [9] hypothesized that the toxicity of anti-glaucoma medications induces fibrosis in the mucous membranes of the lacrimal system.…”

Section: Discussionmentioning

confidence: 99%

“…The etiology of nasolacrimal duct obstruction (NLDO) has not been completely elucidated; however, idiopathic inflammation and fibrosis are known to lead to nasolacrimal duct (NLD) stenosis [1]. According to previous studies, 5-23% [2][3][4] of patients are prediagnosed with glaucoma when they are diagnosed with lacrimal drainage system obstruction. Anti-glaucoma medications may induce ocular surface diseases (OSD) such as conjunctival inflammation and subconjunctival fibrosis in patients [5,6].…”

Section: Introductionmentioning

confidence: 99%

“…The prevalence of OSD in patients with glaucoma due to the use of anti-glaucoma medications has been reported to be 17-52.3% in Asian populations and 40-60% in Western populations [5,7]. Active ingredients, preservatives, and excipients of anti-glaucoma medications are thought to cause ocular surface toxicity [3,7,8]. Several studies have inferred that anti-glaucoma medications may induce inflammation and fibrosis in the NLD mucosa, like how they affect the ocular surface, potentially leading to NLDO development [3,9].…”

Section: Introductionmentioning

confidence: 99%

“…Active ingredients, preservatives, and excipients of anti-glaucoma medications are thought to cause ocular surface toxicity [3,7,8]. Several studies have inferred that anti-glaucoma medications may induce inflammation and fibrosis in the NLD mucosa, like how they affect the ocular surface, potentially leading to NLDO development [3,9].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Effects of Topical Anti-Glaucoma Medications on Outcomes of Endoscopic Dacryocystorhinostomy: Comparison with Age- and Sex-Matched Controls

Lee,

Lim,

et al. 2024

JCM

View full text Add to dashboard Cite

Background: This study analyzed the effects of topical anti-glaucoma medications on the surgical outcomes of endoscopic dacryocystorhinostomy (EDCR) in nasolacrimal duct obstruction (NLDO). Methods: This retrospective study included patients who underwent EDCR for NLDO between September 2012 and April 2021. Thirty patients with topical anti-glaucoma medications and 90 age- and sex-matched controls were included. Results: The success rate of EDCR was higher in the control group than in the anti-glaucoma group (97.8% vs. 86.7%, p = 0.034). Univariate and multivariate logistic regression analyses identified prostaglandin analogs as the most influential risk factor for EDCR success among anti-glaucoma medication ingredients (p = 0.005). The success rate of the group containing all four anti-glaucoma medication ingredients was statistically significant (p = 0.010). The success rate was significantly different in the group of patients who used anti-glaucoma medication for >24 months (p = 0.019). When multiplying the number of drug ingredients by the duration in months, the group > 69 showed a significantly decreased success rate (p = 0.022). Multivariate logistic regression analysis identified the number of anti-glaucoma medications as the most significant risk factor for EDCR success (odds ratio, 0.437; 95% confidence interval, 0.247 to 0.772; p = 0.004). Conclusions: The authors suggest that the anti-glaucoma medications might cause NLDO and increase the failure rate after EDCR. Therefore, when performing EDCR in patients using topical anti-glaucoma medications, surgeons should consider the possibility of increased recurrence after EDCR in clinical outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Effects of Topical Anti-Glaucoma Medications on Outcomes of Endoscopic Dacryocystorhinostomy: Comparison with Age- and Sex-Matched Controls

Lee,

Lim,

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

Role of ocular hypertensives on outcome of dacryocystorhinostomy

Goel

Gaonker

2022

Eye

View full text Add to dashboard Cite

External dacryocystorhinostomy: A critical overview of the current evidence

Locatello,

De Zan,

Tarantini

et al. 2024

European Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose External dacryocystorhinostomy (ext-DCR) is still considered the gold standard in the treatment of distal lacrimal duct obstruction. Despite an overall high success rate, some patients do relapse after surgery and the ideal perioperative management has not been identified yet. The purpose of this study is to critically discuss the published evidence in the last five years on the medical and surgical management of external dacryocystorhinostomy. Furthermore, the drawbacks of the available literature and the perspectives in this field will be also highlighted. Methods Systematic review of the literature in the last 5 years by using PubMed and Google Scholar. Results A total of 64 articles were included. Many technical modifications and surgical refinements have been proposed but a formal comparison among the various techniques is hampered by methodological heterogeneity. The use of local anesthesia, and the perioperative adjunctive techniques to reduce the risk of restenosis are also gaining popularity but the level of evidence remains weak. Conclusion Ext-DCR offers satisfactory clinical outcomes even though there are many gray areas that need to be addressed in future high-quality studies.

show abstract

Do topical ocular antihypertensives affect Dacryocystorhinostomy outcomes: The Coventry experience

Cited by 4 publications

References 18 publications

Effects of Topical Anti-Glaucoma Medications on Outcomes of Endoscopic Dacryocystorhinostomy: Comparison with Age- and Sex-Matched Controls

Effects of Topical Anti-Glaucoma Medications on Outcomes of Endoscopic Dacryocystorhinostomy: Comparison with Age- and Sex-Matched Controls

Role of ocular hypertensives on outcome of dacryocystorhinostomy

External dacryocystorhinostomy: A critical overview of the current evidence

Contact Info

Product

Resources

About